A Multicenter, Open-Label, Single Agent, Two-Stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Malignant Glioma.
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Rilotumumab (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors Amgen
- 06 Feb 2014 According to ClinicalTrials.gov record trial status changed to completed.
- 09 Dec 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 21 Apr 2011 Status changed from active, no longer recruiting to discontinued.